Compare $ALLO vs $RZLT | Chartloom

Compare

$ALLO vs $RZLT

Allogene Therapeutics Inc · Rezolute Inc

ALLO

Allogene Therapeutics Inc

RZLT

Rezolute Inc

Compare $ALLO vs $RZLT

Comparing Allogene Therapeutics Inc and Rezolute Inc

ALLOAllogene Therapeutics Inc

RZLTRezolute Inc

ALLOAllogene Therapeutics Inc

Market cap

$504M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

39,713.68x

Rev growth (TTM)

—

YTD performance

8.1%

52W performance

-0.7%

FCF yield

-20.4%

RZLTRezolute Inc

Market cap

$469M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

124.9%

52W performance

-44.2%

FCF yield

-13.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ALLO

RZLT

Detailed metrics comparison

ALLO

Allogene Therapeutics Inc

RZLT

Rezolute Inc

Market Cap

ALLO$504M

RZLT$469M

Enterprise Value

ALLO$465M

RZLT$458M

Price

ALLO$1.46

RZLT$4.87

P/E Ratio

ALLON/A

RZLTN/A

P/S Ratio

ALLO108.60x

RZLT0.00x

EV/Sales

ALLO100.28x

RZLT0.00x

EV/EBITDA

ALLO0.00x

RZLT0.00x

P/B Ratio

ALLO1.19x

RZLT3.85x

P/FCF Ratio

ALLON/A

RZLTN/A

EV/FCF

ALLO-4.54x

RZLT-7.09x

PEG Ratio

ALLON/A

RZLTN/A

Forward P/E (NTM)

ALLON/A

RZLTN/A

Forward P/S (NTM)

ALLO39,713.68x

RZLTN/A

Revenue (TTM)

ALLO$5M

RZLT$0

Revenue Growth (YoY)

ALLON/A

RZLTN/A

Forward Rev Growth

ALLO219.7%

RZLT2194.8%

Gross Margin (TTM)

ALLO0.0%

RZLT0.0%

Operating Margin (TTM)

ALLO0.0%

RZLT0.0%

EBITDA Margin (TTM)

ALLO-2703.1%

RZLT0.0%

Net Margin (TTM)

ALLO-2648.4%

RZLT0.0%

FCF Margin (TTM)

ALLO-2211.2%

RZLTN/A

Net Income (TTM)

ALLO$-123M

RZLT$-78M

FCF (TTM)

ALLO$-103M

RZLT$-65M

EPS (TTM)

ALLO-$0.37

RZLT-$0.74

ROE (TTM)

ALLO-3531.0%

RZLT-6299.0%

ROA (TTM)

ALLO-2622.0%

RZLT-5794.0%

ROIC (TTM)

ALLO-3531.0%

RZLT-6299.0%

Cash

ALLO$39M

RZLT$11M

Debt

ALLO$0

RZLT$0

Net Cash/Debt

ALLO$39M

RZLT$11M

Current Ratio (TTM)

ALLO10.72x

RZLT9.68x

Quick Ratio (TTM)

ALLO10.55x

RZLT9.44x

Debt/Equity (TTM)

ALLO0.00x

RZLT0.00x

Debt/Assets (TTM)

ALLO0.0%

RZLT0.0%

Interest Coverage (TTM)

ALLON/A

RZLTN/A

Net Debt/EBITDA (TTM)

ALLO0.00x

RZLT0.00x

Beta

ALLO0.75

RZLT0.58

52W Performance

ALLO-0.7%

RZLT-44.2%

YTD Performance

ALLO8.1%

RZLT124.9%

% from 52W High

ALLO-67.3%

RZLT-57.5%

% from 52W Low

ALLO40.4%

RZLT355.1%

Asset Turnover (TTM)

ALLO0.01x

RZLT0.00x

FCF Yield (TTM)

ALLO-20.4%

RZLT-13.8%

Earnings Yield (TTM)

ALLO-24.4%

RZLT-16.5%

Dividend Yield (TTM)

ALLON/A

RZLTN/A

Rule of 40

ALLO-2,211.2

RZLT0.0

EV/GP/RG

ALLON/A

RZLTN/A

Ticker research

View ALLO research View RZLT research

Metric	ALLO Allogene Therapeutics Inc	RZLT Rezolute Inc
Market & Valuation
Market Cap	$504M	$469M
Enterprise Value	$465M	$458M
Price	$1.46	$4.87
P/E Ratio	N/A	N/A
P/S Ratio	108.60x	0.00x
EV/Sales	100.28x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.19x	3.85x
P/FCF Ratio	N/A	N/A
EV/FCF	-4.54x	-7.09x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	39,713.68x	N/A
Revenue & Growth
Revenue (TTM)	$5M	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	219.7%	2194.8%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-2703.1%	0.0%
Net Margin (TTM)	-2648.4%	0.0%
FCF Margin (TTM)	-2211.2%	N/A
Net Income (TTM)	$-123M	$-78M
FCF (TTM)	$-103M	$-65M
EPS (TTM)	-$0.37	-$0.74
ROE (TTM)	-3531.0%	-6299.0%
ROA (TTM)	-2622.0%	-5794.0%
ROIC (TTM)	-3531.0%	-6299.0%
Financial Health
Cash	$39M	$11M
Debt	$0	$0
Net Cash/Debt	$39M	$11M
Current Ratio (TTM)	10.72x	9.68x
Quick Ratio (TTM)	10.55x	9.44x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.75	0.58
52W Performance	-0.7%	-44.2%
YTD Performance	8.1%	124.9%
% from 52W High	-67.3%	-57.5%
% from 52W Low	40.4%	355.1%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.00x
FCF Yield (TTM)	-20.4%	-13.8%
Earnings Yield (TTM)	-24.4%	-16.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-2,211.2	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ALLO research	View RZLT research

Valuation

P/S Ratio

RZLT

0.00x

ALLO

108.60x

EV/FCF

RZLT

-7.09x

ALLO

-4.54x

Growth & revenue

Forward Revenue Growth

RZLT

2194.8%

ALLO

219.7%

Profitability & performance

Gross Margin

ALLO

0.0%

RZLT

0.0%

ROE

ALLO

-3531.0%

RZLT

-6299.0%

FCF Yield %

RZLT

-13.8%

ALLO

-20.4%

52-Week Performance

ALLO

-0.7%

RZLT

-44.2%

Detailed metrics comparison

ALLO

Allogene Therapeutics Inc

RZLT

Rezolute Inc

Market Cap

ALLO$504M

RZLT$469M

Enterprise Value

ALLO$465M

RZLT$458M

Price

ALLO$1.46

RZLT$4.87

P/E Ratio

ALLON/A

RZLTN/A

P/S Ratio

ALLO108.60x

RZLT0.00x

EV/Sales

ALLO100.28x

RZLT0.00x

EV/EBITDA

ALLO0.00x

RZLT0.00x

P/B Ratio

ALLO1.19x

RZLT3.85x

P/FCF Ratio

ALLON/A

RZLTN/A

EV/FCF

ALLO-4.54x

RZLT-7.09x

PEG Ratio

ALLON/A

RZLTN/A

Forward P/E (NTM)

ALLON/A

RZLTN/A

Forward P/S (NTM)

ALLO39,713.68x

RZLTN/A

Revenue (TTM)

ALLO$5M

RZLT$0

Revenue Growth (YoY)

ALLON/A

RZLTN/A

Forward Rev Growth

ALLO219.7%

RZLT2194.8%

Gross Margin (TTM)

ALLO0.0%

RZLT0.0%

Operating Margin (TTM)

ALLO0.0%

RZLT0.0%

EBITDA Margin (TTM)

ALLO-2703.1%

RZLT0.0%

Net Margin (TTM)

ALLO-2648.4%

RZLT0.0%

FCF Margin (TTM)

ALLO-2211.2%

RZLTN/A

Net Income (TTM)

ALLO$-123M

RZLT$-78M

FCF (TTM)

ALLO$-103M

RZLT$-65M

EPS (TTM)

ALLO-$0.37

RZLT-$0.74

ROE (TTM)

ALLO-3531.0%

RZLT-6299.0%

ROA (TTM)

ALLO-2622.0%

RZLT-5794.0%

ROIC (TTM)

ALLO-3531.0%

RZLT-6299.0%

Cash

ALLO$39M

RZLT$11M

Debt

ALLO$0

RZLT$0

Net Cash/Debt

ALLO$39M

RZLT$11M

Current Ratio (TTM)

ALLO10.72x

RZLT9.68x

Quick Ratio (TTM)

ALLO10.55x

RZLT9.44x

Debt/Equity (TTM)

ALLO0.00x

RZLT0.00x

Debt/Assets (TTM)

ALLO0.0%

RZLT0.0%

Interest Coverage (TTM)

ALLON/A

RZLTN/A

Net Debt/EBITDA (TTM)

ALLO0.00x

RZLT0.00x

Beta

ALLO0.75

RZLT0.58

52W Performance

ALLO-0.7%

RZLT-44.2%

YTD Performance

ALLO8.1%

RZLT124.9%

% from 52W High

ALLO-67.3%

RZLT-57.5%

% from 52W Low

ALLO40.4%

RZLT355.1%

Asset Turnover (TTM)

ALLO0.01x

RZLT0.00x

FCF Yield (TTM)

ALLO-20.4%

RZLT-13.8%

Earnings Yield (TTM)

ALLO-24.4%

RZLT-16.5%

Dividend Yield (TTM)

ALLON/A

RZLTN/A

Rule of 40

ALLO-2,211.2

RZLT0.0

EV/GP/RG

ALLON/A

RZLTN/A

Ticker research

View ALLO research View RZLT research

Metric	ALLO Allogene Therapeutics Inc	RZLT Rezolute Inc
Market & Valuation
Market Cap	$504M	$469M
Enterprise Value	$465M	$458M
Price	$1.46	$4.87
P/E Ratio	N/A	N/A
P/S Ratio	108.60x	0.00x
EV/Sales	100.28x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.19x	3.85x
P/FCF Ratio	N/A	N/A
EV/FCF	-4.54x	-7.09x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	39,713.68x	N/A
Revenue & Growth
Revenue (TTM)	$5M	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	219.7%	2194.8%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-2703.1%	0.0%
Net Margin (TTM)	-2648.4%	0.0%
FCF Margin (TTM)	-2211.2%	N/A
Net Income (TTM)	$-123M	$-78M
FCF (TTM)	$-103M	$-65M
EPS (TTM)	-$0.37	-$0.74
ROE (TTM)	-3531.0%	-6299.0%
ROA (TTM)	-2622.0%	-5794.0%
ROIC (TTM)	-3531.0%	-6299.0%
Financial Health
Cash	$39M	$11M
Debt	$0	$0
Net Cash/Debt	$39M	$11M
Current Ratio (TTM)	10.72x	9.68x
Quick Ratio (TTM)	10.55x	9.44x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.75	0.58
52W Performance	-0.7%	-44.2%
YTD Performance	8.1%	124.9%
% from 52W High	-67.3%	-57.5%
% from 52W Low	40.4%	355.1%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.00x
FCF Yield (TTM)	-20.4%	-13.8%
Earnings Yield (TTM)	-24.4%	-16.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-2,211.2	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ALLO research	View RZLT research